Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000416

Drug Information
NameAG-14699
SynonymsAG-014699; AG-14699; AG-014447; PF-01367338; EC-000.2323; S1098_Selleck; CID9931953; CID 9931953; AG-14447
CompanyPfizer
IndicationCancer
[ICD9: 140-229   ICD10: C00-C96]
Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C19H18FN3O.H3O4P/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)
15-8-13(20)9-16(23-18)17(14)15;1-5(2,3)4/h2-5,8-9,21,23H,6-7,10H2
,1H3,(H,22,24);(H3,1,2,3,4)
InChIKeyFCCGJTKEKXUBFZ-UHFFFAOYSA-N
Canonical SMILESCNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)N2)F.OP(=O)(O)O    
CAS NumberCAS 83420-94-4
FormulaC19H21FN3O5P
PubChem Compound IDCID 9931953.
PubChem Substance IDSID 14904848.
TargetPoly [ADP-ribose] polymerase 1Inhibitor[1]
Ref 1Pfizer. Product Development Pipeline. March 31 2009. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543